Stock Code
688016.SH
Stock Code
688016.SH
Technology Innovation, People Centric
Adhering to the mission of providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, Endovastec™ is committed to building a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.
Products
Endovastec™ focuses on the research and development (R&D), manufacturing, sales and services of aortic, peripheral vascular and tumor intervention devices,and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, drug-coated balloon dilatation catheters, balloon dilatation catheters, vena cava filters and snare retrieval kits etc.
News
Endovastec™ Fishhawk™ Mechanical Thrombectomy Device Receives NMPA Approval in China
Shanghai, China – May 7, 2026 – Shanghai MicroPort Endovastec Technology Co., Ltd. (Endovastec™) announced that its Fishhawk™ Mechanical Thrombectomy Device (Fishhawk™) has received marketing approval from the National Medical Products Administration (NMPA) of China. First admitted to the NMPA Green Channel for Innovative Medical Devices in 2022, Fishhawk™ provides a vital new treatment option for the percutaneous endovascular removal of acute iliac and femoral Deep Venous Thrombosis (DVT).
08 May 2026
 - 副本.png)
Endovastec™’s SunFlow™ Drug-Eluting Peripheral Stent System Granted NMPA Green Channel Designation for Innovative Medical Devices
Shanghai, China – May 7, 2026 – Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) recently announced that its SunFlow™ Drug-Eluting Peripheral Stent System (“SunFlow™”) has been granted access to the National Medical Products Administration (NMPA) special review procedures for innovative medical devices, known as the Green Channel. This marks the tenth product from Endovastec™ to receive this designation.
07 May 2026
Endovastec™ Announces Annual Results for 2025: Solid Growth with Continued Innovation and Global Expansion
The Company continued to advance its dual strategic of innovation-driven growth and global expansion, maintaining steady and positive business performance.
30 Mar 2026
About us
News
Products
Investor Relations
Telephone:(86) (21) 38139300
Address:Building #1,3399 Kangxin Rd., SIMZ Century Medicine Park, Shanghai201318,P.R. China
Fax:(86) (21) 33750026
©Copyright 2002-2025, Shanghai MicroPort Endovascular MedTech（Group）Co., Ltd.
Internet Drug Information Service Qualification Certificate No.: (Hu) - Non-operating -2024-0188
Website record/ license No.：沪ICP备14048493号-1 
HGWA Bei No.31011502014536
The registered trademarks of “微创", "MicroPort" and"
" are registered trademarks of Shanghai MicroPort Medical (Group) Co., Ltd., they have been authorized to be used by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., and no other party shall use such trademarks without prior written permission thereof.
